Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Griffiths, J; Jenkins, P; Vargova, M; Bowler, U; Juszczak, E; King, A; Linsell, L; Murray, D; Partlett, C; Patel, M; Berrington, J; Dorling, J; Embleton, N; Heath, P; Oddie, S; McGuire, W

Women's Health Collection

Journal article

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Abstract:: Background

Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow’s milk, prevents infections and associated complications.

Methods

In this randomised, placebo-controlled trial, very preterm infants (born before 32 weeks’ gestation) in 37 UK hospitals were allocated randomly (1:1) within 72 hours after birth to receive enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day) versus sucrose (same dose) once daily until 34 weeks’ postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers and outcomes assessors were unaware of group assignment. The primary outcome was microbiologically-confirmed or clinically-suspected late-onset infection (occurring >72 hours after birth). The trial was registered with the International Standard Randomised Controlled Trial Number 88261002.

Findings

We recruited 2203 participants between May 2014 and September 2017. Four infants had consent withdrawn or unconfirmed leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants were available for inclusion in the intention-to-treat analyses. In the intervention group, 316/1093 (28.9%) infants acquired a late-onset infection versus 334/1089 (30.7%) in the control group: risk ratio (RR) adjusted for minimisation factors 0.95 (95% confidence interval [CI] 0.86, 1.04). Pre-specified subgroup analyses did not show statistically significant interactions for gestation at birth (completed weeks’) or type of enteral milk received (human, formula, or both).

Interpretation

Enteral supplementation with bovine lactoferrin does not reduce the incidence of late-onset infection in very preterm infants.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Griffiths, J., Jenkins, P., Vargova, M., Bowler, U., Juszczak, E., King, A., Linsell, L., Murray, D., Partlett, C., Patel, M., Berrington, J., Dorling, J., Embleton, N., Heath, P., Oddie, S., & McGuire, W. (2019). Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. Lancet, 393(10170), 423–433.

MLA Style

Griffiths, J, et al. “Enteral Lactoferrin Supplementation for Very Preterm Infants: a Randomised Placebo-Controlled Trial.” Lancet, vol. 393, no. 10170, 2019, pp. 423–33.

Chicago Style

Griffiths, J, P Jenkins, M Vargova, et al. 2019. “Enteral Lactoferrin Supplementation for Very Preterm Infants: a Randomised Placebo-Controlled Trial.” Lancet 393 (10170): 423–33.
Print